Physician profile
Elise E Schriver
NPI 1891701322
$7,182.51
in general payments reported to CMS, 2019-2025
44 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $578 · 2021: $738 · 2022: $845 · 2023: $938 · 2024: $1,241 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $998.98 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $918.04 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $826.74 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.07 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $560.66 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $438.20 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $379.62 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $367.04 | 2020-2025 | Winrevair, Zerbaxa, Recarbrio |
| Genentech USA, INC. | $279.00 | 2019-2022 | |
| Mylan Specialty L.P. | $219.70 | 2019-2024 | Yupelri |
| Abbvie INC. | $216.48 | 2021-2025 | Avycaz, Teflaro |
| Genzyme Corporation | $149.51 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $131.66 | 2024-2025 | Dupixent, Libtayo |
| Amgen INC. | $121.20 | 2023-2025 | Tezspire |
| Baxter Healthcare | $97.82 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Schriver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.